Ashfield Capital Partners LLC cut its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 2.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 63,847 shares of the company’s stock after selling 1,314 shares during the quarter. Ashfield Capital Partners LLC’s holdings in Henry Schein were worth $5,429,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. McAdam LLC bought a new position in shares of Henry Schein during the 3rd quarter valued at approximately $104,000. NEXT Financial Group Inc bought a new position in shares of Henry Schein during the 3rd quarter valued at approximately $103,000. Squar Milner Financial Services LLC bought a new position in shares of Henry Schein during the 2nd quarter valued at approximately $120,000. Piedmont Investment Advisors LLC bought a new position in shares of Henry Schein during the 2nd quarter valued at approximately $130,000. Finally, Fuller & Thaler Asset Management Inc. grew its stake in shares of Henry Schein by 57.1% during the 2nd quarter. Fuller & Thaler Asset Management Inc. now owns 2,200 shares of the company’s stock valued at $160,000 after acquiring an additional 800 shares during the period.
NASDAQ HSIC opened at $83.51 on Monday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 0.68 and a current ratio of 1.29. Henry Schein, Inc. has a 12 month low of $62.56 and a 12 month high of $90.52. The company has a market capitalization of $12.79 billion, a P/E ratio of 23.20, a price-to-earnings-growth ratio of 2.55 and a beta of 0.87.
Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Monday, August 6th. The company reported $1.04 EPS for the quarter, topping the Zacks’ consensus estimate of $1.01 by $0.03. Henry Schein had a return on equity of 20.40% and a net margin of 3.15%. The company had revenue of $3.33 billion for the quarter, compared to analysts’ expectations of $3.31 billion. During the same period in the previous year, the firm earned $0.88 EPS. The firm’s revenue was up 8.7% compared to the same quarter last year. As a group, equities analysts forecast that Henry Schein, Inc. will post 4.12 earnings per share for the current year.
HSIC has been the subject of a number of recent research reports. BidaskClub upgraded Henry Schein from a “hold” rating to a “buy” rating in a research note on Wednesday, August 22nd. Zacks Investment Research upgraded Henry Schein from a “hold” rating to a “buy” rating and set a $85.00 price objective for the company in a research note on Tuesday, July 10th. Leerink Swann set a $100.00 price objective on Henry Schein and gave the company a “buy” rating in a research note on Tuesday, August 7th. Barrington Research reiterated a “buy” rating and set a $92.00 price objective on shares of Henry Schein in a research note on Tuesday, August 7th. Finally, Craig Hallum boosted their price objective on Henry Schein from $83.00 to $96.00 and gave the company a “buy” rating in a research note on Tuesday, August 7th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. Henry Schein has an average rating of “Hold” and an average price target of $83.53.
About Henry Schein
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
See Also: Technical Analysis
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC).
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.